This is a Phase I study to evaluate the safety, tolerability, and efficacy of TQB2922 for injection in subjects with advanced cancers
Subjects voluntarily join this study, sign the informed consent form, and have good compliance；
Age: 18-75 years; Eastern Cooperative Oncology Group (ECOG) score: 0-1 ; Expected survival of more than 3 months；
Histologically or cytologically diagnosed with advanced cancers;
Subjects with advanced malignancies who have failed standard therapy or lack effective treatment;
Current concomitant or ever presented with other malignancies within 2 years prior to the first dose;
Unresolved toxicity of Grade 1 or above according to CTCAE due to any prior anti-tumor therapy;
Significant surgical treatment, biopsy, or significant traumatic injury within 28 days prior to the first dose;
Long-term unhealed wounds or fractures